Disrupting DNA Repair May Help Defeat Drug-Resistant Cancer

Cancer’s ability to adapt is one of its most dangerous traits — especially when tumors stop responding to life-saving drugs. But a new study in Nature Communications suggests that even drug-resistant cancers may have a hidden weakness.

Instead of targeting genetic mutations directly, researchers have found a way to dismantle the very system cancer cells rely on to survive. By disrupting the machinery that repairs damaged DNA, scientists were able to make resistant tumors vulnerable again, potentially reopening the door for treatments that have stopped working.

“This study demonstrates that controlling the stability of DNA repair proteins can directly impact cancer cell survival. It also highlights a new therapeutic direction for overcoming drug resistance,” said co-corresponding author Myung Kyungjae in a press release.

A New Strategy to Fight Drug-Resistant Cancer

Many modern cancer therapies, including PARP inhibitors, are designed to exploit a key vulnerability: cancer cells’ dependence on DNA repair. These treatments work by overwhelming tumor cells with damage they can’t fix. But over time, some cancers adapt, restoring their repair systems and becoming resistant.

This new research takes a different approach to exploitation. Instead of trying to outpace cancer’s genetic changes, researchers targeted the stability of the proteins responsible for DNA repair.

Using a specialized screening method, the team identified a small molecule called UNI418. When introduced to cancer cells, UNI418 significantly reduced the levels of critical DNA repair. Without these proteins, cancer cells lost their ability to recover from DNA damage, even if they had previously developed resistance.

“We identified a mechanism in which key DNA repair proteins are actively degraded inside the cell,” explained co-corresponding author Lee Joo-Young. “This provides a new way to regulate homologous recombination beyond genetic mutations.”

The result is a kind of forced vulnerability. When exposed to this treatment, even resilient cancer cells become sensitive to treatments again, offering a potential path to extend the effectiveness of existing therapies.

Read More: New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer

What Is DNA Repair?

An important aspect of this new treatment is a process called homologous recombination, which is a precise way cells repair their broken DNA. It relies on specialized proteins to accurately restore damaged genetic material.

Under normal conditions, this system is essential for healthy cells. But for cancer cells, it becomes a survival tool.

Tumor cells experience constant stress and DNA damage as they rapidly grow. Their ability to repair that damage allows them to survive treatments that would otherwise destroy them. That’s why therapies targeting DNA repair are so effective — but only for a limited time.

What makes this new discovery different is that, rather than blocking repair pathways outright, UNI418 triggers a natural protein disposal system inside the cell. This system targets key repair proteins for destruction, effectively dismantling the repair process from within.

As those proteins disappear, cancer cells are left exposed and unable to keep up with their accumulating damage.

What This Means for the Future of Cancer Treatment

This research highlights a broader shift in how scientists are thinking about treating cancer. Instead of just targeting genes, as in previous cancer treatments, this new process controls the proteins that those genes produce.

And the treatment is proving to be effective. In laboratory experiments, UNI418 didn’t just improve treatment outcomes but also restored effectiveness in cancers that had already become treatment-resistant.

“By weakening the DNA repair system, we can re-sensitize tumors that have become resistant to existing therapies. This suggests a new strategy for expanding the effectiveness of PARP inhibitors,” said Kyungjae.

If future studies can replicate these laboratory findings in clinical patients, this approach could help extend the lifespan of existing cancer therapies and offer new hope for those facing the drug-resistant forms of cancer.

This article is not offering medical advice and should be used for informational purposes only.

Article Sources

Our writers at Discovermagazine.com use peer-reviewed studies and high-quality sources for our articles, and our editors review for scientific accuracy and editorial standards. Review the sources used below for this article: